Longeveron (NASDAQ:LGVN) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Longeveron (NASDAQ:LGVN) to a hold rating in a research report report published on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Longeveron in a research note on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $3.00.

Longeveron Price Performance

NASDAQ:LGVN opened at $1.10 on Friday. The business’s 50-day moving average price is $0.82 and its 200 day moving average price is $0.72. The firm has a market cap of $25.60 million, a P/E ratio of -0.86 and a beta of -0.18. Longeveron has a 52-week low of $0.48 and a 52-week high of $1.83. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 0.03.

Longeveron (NASDAQ:LGVN) last released its earnings results on Tuesday, March 17th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.20. The firm had revenue of $0.37 million for the quarter, compared to analyst estimates of $0.11 million. Longeveron had a negative return on equity of 199.79% and a negative net margin of 1,893.58%. As a group, sell-side analysts predict that Longeveron will post -3.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Longeveron

An institutional investor recently bought a new position in Longeveron stock. XTX Topco Ltd purchased a new position in Longeveron Inc. (NASDAQ:LGVN) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned approximately 0.32% of Longeveron at the end of the most recent quarter. 10.01% of the stock is owned by institutional investors.

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.